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ABSTRACT
Background and Objectives: The effectiveness of adjunct balloon dilation after drug-eluting 
stent (DES) deployment has not been sufficiently evaluated. We evaluated whether adjunct 
balloon dilation was associated with a reduction in major adverse cardiac events (MACEs) 
after long everolimus-eluting stents (EESs) implantation.
Subjects and Methods: Drawing from 2 randomized trials, a total of 1,672 patients treated 
with long EES were analyzed. Of 1,672 patients, 1,061 patients (64%) received post-stent 
adjunct balloon dilation. MACE, defined as a composite of cardiac death, myocardial 
infarction, and target-lesion revascularization (TLR), was compared between patients who 
received post-stent adjunct balloon dilation and patients who did not in 595 propensity score-
matched pairs.
Results: For the matched population, MACE occurred in 29 patients (4.9%) who received 
adjunct balloon dilation and in 29 patients (4.9%) who did not (hazard ratio [HR], 1.01; 
95% confidence interval [CI], 0.60–1.69; p=0.972). However, significant interactions were 
observed among the subgroups for clinical presentation and vessel size. Adjunct balloon 
dilation was more favored within the subset of patients with stable angina vs. the subset of 
patients with acute coronary syndrome (p for interaction=0.037), and within the subset of 
lesions with small vessel diameter (reference vessel diameter [RVD] <3 mm) vs. the subset of 
lesions with larger vessel diameter (RVD ≥3 mm; p for interaction=0.027).
Conclusion: Adjunct balloon dilation was not associated with MACE reduction at 1 year 
among patients requiring long EES implantation. However, post-stent adjunct balloon 
dilation may be necessary for patients requiring long EES implantation who present with 
stable angina or for lesions with small vessel diameters.
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INTRODUCTION
Post-stent adjunct balloon dilation is often used to achieve optimal stent expansion and 
complete apposition of stent struts against the vessel wall.1-3) Conversely, aggressive stent 
inflation with higher pressure may also be associated with increased neointimal hyperplasia 
due to the inflammatory response to vessel wall injury, and can lead to increased occurrence 
of peri-procedural myocardial infarction by thrombus or plaque debris embolization.4-6) In 
this context, post-stent adjunct balloon dilation is inconsistently practiced and is highly 
dependent on the individual operators' decisions. Adjunct balloon dilation has not been 
routinely performed in most randomized trials on the use of drug-eluting stents (DESs). 
Additionally, the clinical efficacy of post-stent adjunct balloon dilation has not been well 
evaluated in patients treated with second-generation DES, although 2 recent studies 
evaluated its efficacy for patients treated with bare-metal stents and first-generation DESs.7)8)
This study evaluated whether adjunct balloon dilation was associated with a reduction in 
major adverse cardiac events (MACEs) after long second-generation DES implantation, 
particularly everolimus-eluting stent (EES), using patient data from 2 randomized trials; 
Impact of intraVascular UltraSound guidance on outcomes of Xience Prime stents in Long 
lesions (IVUS-XPL) and REal Safety and Efficacy of 3-month dual antiplatelet Therapy 
following Endeavor zotarolimus-eluting stent implantation (RESET).9)10)
SUBJECTS AND METHODS
Study population
We identified patients treated with long EES (implanted stent ≥28 mm in length, Xience; 
Abbott Vascular, Santa Clara, CA, USA) from 2 recently conducted randomized trials. In the 
IVUS-XPL trial, which examined the superiority of intravascular ultrasound (IVUS)-guidance 
DES implantation for long coronary lesions, a total of 1,400 patients were randomized 
to receive either IVUS- or angiography-guided EES implantation.9) The RESET trial was 
a noninferiority trial comparing patients who had received 3 months of dual antiplatelet 
therapy following implantation of the Endeavor sprint zotarolimus-eluting stent (Medtronic, 
Inc., Santa Rosa, CA, USA) and 12 months of dual antiplatelet therapy following implantation 
of another DES.10) In the prespecified long lesion subset of this study,10)11) 543 patients were 
randomly allocated to receive either IVUS- or angiography-guided DES implantation. In this 
subset, the Endeavor sprint zotarolimus-eluting stent (n=271) or the EES (n=272) were also 
randomized. Finally, a total of 1,672 patients were included in this study, with 1,400 patients 
from the IVUS-XPL trial and 272 patients from the pre-specified long lesion subset of the 
RESET trial with EES implantation. Detailed protocols of these trials have been previously 
described.9-11) The study protocol was approved by the Institutional Review Boards at each 
participating center, and all participants gave written informed consent.
Stent implantation
EES implantation was performed according to standard techniques. If a lesion could not 
be covered with a single stent, overlapping stents were used. For patients allocated to the 
angiography-guided group, stent size, and length were chosen by visual estimation. Adjunct 
high-pressure dilation was performed if an optimal result was not achieved, which was 
defined as angiographic residual diameter stenosis <30% and absence of angiographically 
detected dissection. For patients allocated to the IVUS-guided group, stent size, and length 
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were selected by online IVUS measurements, and adjunct high-pressure dilation was 
performed according to the discretion of operators based on IVUS findings. In the IVUS-XPL 
trial, the following IVUS criterion for stent optimization was used: a minimal lumen cross-
sectional area greater than the lumen cross sectional area at the distal reference segments.9) 
After EES implantation, aspirin (at a dose of 100 mg/day) was prescribed indefinitely. 
The administration of clopidogrel (at a dose of 75 mg/day) depended on the randomized 
assignments in the previous trials.9-11)
Angiographic analyses
Angiographic measurements were performed by analysts who were blinded to patient and 
treatment assignments in an independent core laboratory at the Cardiovascular Research 
Center, Seoul, Korea. Before and after EES implantation, an off-line quantitative coronary 
angiographic system (CASS system; Pie Medical Instruments, Maastricht, The Netherlands) 
was used to perform quantitative coronary angiography analyses. Using a guiding catheter for 
magnification-calibration, the diameters of the reference vessel (the average of the proximal 
and distal reference lumen diameters) and the minimal luminal diameter were measured 
before and after EES implantation. These measurements were made from diastolic frames 
in a single matched view, revealing the smallest minimal luminal diameter. Pre-intervention 
lesion length was measured as the distance in millimeters from the proximal to the distal 
shoulder of the lesion when projected with the least foreshortening.12)
Follow-up and study endpoints
After stent implantation, clinical assessment was performed in the hospital and at 1, 3, 6, and 
12 months after discharge. Follow-up assessments were performed during a clinic visit or by 
telephone interview. MACE was defined as cardiac death, target lesion-related myocardial 
infarction, or ischemia-driven target-lesion revascularization (TLR).
Clinical events were defined according to the Academic Research Consortium and an expert 
consensus document that defined the third universal definition for myocardial infarction.13)14) 
All deaths were considered cardiac-related unless an unequivocal non-cardiac cause could be 
established.13) At 1 year follow-up, a target lesion-related myocardial infarction was defined by 
the following parameters: the presence of clinical symptoms, electrocardiographic changes, 
or abnormal imaging findings indicative of myocardial infarction, and an increase in the 
creatine kinase myocardial band fraction above the upper normal limits or an increase in 
troponin-T/troponin-I above the 99th percentile of the upper normal limit. The territory 
of the myocardial infarction was supplied by the coronary artery containing the target 
lesions.9)14) Ischemia-driven TLR was defined as repeat percutaneous coronary intervention 
to or bypass surgery of the target lesion with; either 1) angiographic diameter stenosis ≥50% 
according to quantitative coronary angiographic analysis with documentation of a positive 
stress test, or 2) angiographic diameter stenosis ≥70% irrespective of the stress test results.13)
Statistical analyses
Categorical variables were reported as numbers and percentages and were compared using 
the χ2 test or Fisher's exact test. Continuous variables were reported as mean±standard 
deviation (SD) and were compared using the Student's t-test. Propensity score matching 
was performed to reduce treatment selection bias and potential confounding factors and to 
adjust for significant differences in patient or lesion characteristics. Propensity scores were 
estimated using a non-parsimonious multiple logistic regression model for treatment with 
adjunct balloon dilation vs. without adjunct balloon dilation. The following variables were 
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selected to calculate the propensity score: age, gender, body mass index (BMI), hypertension, 
diabetes mellitus (DM), dyslipidemia, current smoker, clinical presentation (stable angina, 
unstable angina, and acute myocardial infarction), number of diseased vessels, number of 
treated lesions per patient, coronary arteries (left anterior descending artery, left circumflex 
artery, and right coronary artery), pre-intervention reference vessel diameter (RVD), pre-
intervention lesion length, use of IVUS, and number of stents per lesion. New propensity 
scores were incorporated to assess the efficacy of adjunct balloon dilation. A local optimal 
algorithm with the caliper method was used to develop propensity score-matched pairs 
without replacement (a 1:1 match). The Hosmer-Lemeshow goodness-of-fit test was used to 
assess the model fit to the data (p=0.534). The C statistic for the model was 0.66. A matching 
caliper of 0.2 SDs of the logit of the estimated propensity score was enforced in order to 
ensure that matches of poor fit were excluded. The matching procedure was performed 
using R packages (R Project, Vienna, Austria), including MatchIt, RItools, and CEM. After 
propensity score matching, covariates were compared with the paired t-test for continuous 
variables and the McNemar test for categorical variables.
Cumulative incidences of MACE at 1 year were calculated using Kaplan-Meier estimates 
and compared using the log-rank test. Although patients could experience more than 1 
MACE component, each patient was assessed until the occurrence of their first event and 
only once during analysis. Subgroup analyses were performed according to the clinical and 
angiographic subgroups. Statistical analyses were performed using IBM SPSS, version 19.0 
(IBM Corporation, New York, NY, USA). All tests were 2-sided and a p value <0.050 was 
considered statistically significant.
RESULTS
Of 1,672 patients, 1,061 (63.5%) received post-stent adjunct balloon dilation using a non-
compliant balloon with an average diameter of 3.09±0.43 mm up to 16.3±4.1 atm. There 
were 595 matched pairs after propensity score matching. Baseline clinical characteristics 
are shown in Table 1. Clinical characteristics were not statistically different in patients 
who received adjunct balloon dilation vs. those who did not for the matched population. 
Angiographic and procedural characteristics according to the practice of post-stent adjunct 
ballooning of the target long lesions are shown in Table 2. Adjunct balloon dilation was 
more frequently undertaken for long target lesions of the left anterior descending artery 
and for use with IVUS for the total population. However, for the matched population, 
angiographic and procedural characteristics were not different between the 2 groups except 
for use with IVUS.
Clinical outcomes at 1-year are shown in Table 3. For the total population, MACE occurred 
in 42 patients (4.1%) who received adjunct balloon dilation and in 31 patients (5.1%) 
who did not, and the difference was not statistically significant (hazard ratio [HR], 0.79; 
95% confidence interval [CI], 0.50–1.26; p=0.315) (Figure 1A). Similarly, for the matched 
population, MACE occurred in 29 patients (4.9%) who received adjunct balloon dilation and 
in 29 patients (4.9%) who did not, and the difference was also not statistically significant 
(HR, 1.01; 95% CI, 0.60–1.69; p=0.972) (Figure 1B). There were no significant differences 
between the 2 groups for any of the measured clinical events including cardiac death, target-
lesion related myocardial infarction, ischemia-driven TLR, and definite or probable stent 
thrombosis for total population and matched population (Table 3).
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Subgroup analyses for the matched population are shown in Figure 2. There were no statistically 
significant interactions among the subgroups for clinical variables of age, sex, hypertension, 
DM, use of IVUS, and lesion length. However, significant interactions were observed among the 
subgroups for clinical presentation and reference vessel size. Adjunct balloon dilation was more 
favored within the subset of patients with stable angina compared with those with acute coronary 
syndrome (p for interaction=0.037) (Figure 3). Adjunct balloon dilation was also more favored 
within the subset of lesions with small vessel diameter (RVD <3 mm) compared with those with 
larger vessel diameter (RVD ≥3 mm; p for interaction=0.027) (Figure 4).
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Table 1. Baseline clinical characteristics
Characteristics Total population Matched population
ABD (+) ABD (−) p value ABD (+) ABD (−) p value
No. of patients 1,061 611 - 595 595 -
Age (years) 64±10 64±9 0.589 63±10 64±9 0.250
Male sex 721 (68) 406 (66) 0.527 406 (68) 398 (67) 0.667
BMI (kg/m2) 24.7±3.0 24.7±2.9 0.919 24.8±3.0 24.7±3.0 0.671
Hypertension 692 (65) 381 (62) 0.239 380 (64) 369 (62) 0.530
DM 376 (35) 213 (35) 0.812 205 (35) 207 (35) 0.951
Dyslipidemia 713 (67) 389 (64) 0.142 372 (63) 379 (64) 0.722
Current smoker 244 (23) 142 (23) 0.909 140 (24) 139 (23) 1.000
Clinical presentation - - 0.371 - - 0.533
Stable angina 559 (53) 302 (49) - 313 (53) 293 (49) -
Unstable angina 354 (33) 212 (35) - 200 (34) 209 (35) -
Acute myocardial infarction 148 (14) 97 (16) - 82 (14) 93 (16) -
No. of diseased vessels - - 0.291 - - 0.564
1 331 (31) 206 (34) - 199 (33) 203 (34) -
2 392 (37) 232 (38) - 215 (36) 224 (38) -
3 338 (32) 173 (28) - 181 (30) 168 (28) -
No. of treated lesions per patient 1.36±0.57 1.42±0.65 0.052 1.40±0.61 1.41±0.64 0.734
Data are expressed as No. of patients (%) or mean±SD. 
ABD = adjunct balloon dilation; BMI = body mass index; DM = diabetes mellitus; SD = standard deviation.
Table 2. Angiographic and procedural characteristics according to the presence of post-stent adjunct balloon dilation of target long lesions
Characteristics Total population Matched population
ABD (+) ABD (−) p value ABD (+) ABD (−) p value
No. of target long lesions 1,061 611 - 595 595 -
Coronary arteries - - 0.075 - - 0.629
Left anterior descending artery 684 (65) 366 (60) - 363 (61) 358 (60) -
Left circumflex artery 155 (15) 88 (14) - 91 (15) 84 (14) -
Right coronary artery 222 (21) 157 (26) - 141 (24) 153 (26) -
Pre-intervention QCA data - - - - - -
RVD (mm) 2.89±0.44 2.86±0.46 0.196 2.87±0.43 2.86±0.46 0.767
Minimum lumen diameter (mm) 0.85±0.42 0.82±0.44 0.199 0.86±0.43 0.82±0.45 0.124
Diameter stenosis (%) 70.4±14.0 71.2±14.7 0.234 70.0±14.4 71.2±14.8 0.092
Lesion length (mm) 35.1±11.2 34.2±10.9 0.138 34.4±10.2 34.3±10.9 0.762
Use of IVUS 613 (58) 234 (40) <0.001 272 (46) 242 (41) 0.019
No. of stents per lesion 1.28±0.51 1.38±0.56 <0.001 1.32±0.53 1.36±0.54 0.155
Coronary perforation 0 0 - 0 0 -
Edge dissection 21 (2) 11 (2) 0.797 11 (2) 11 (2) 0.999
No reflow phenomenon 2 (0.2) 4 (0.7) 0.125 1 (0.2) 4 (0.7) 0.250
Post-intervention QCA data - - - - - -
RVD (mm) 3.00±0.43 2.97±0.45 0.064 2.99±0.41 2.97±0.44 0.325
Minimum lumen diameter (mm) 2.60±0.41 2.55±0.39 0.007 2.58±0.40 2.56±0.39 0.196
Diameter stenosis (%) 13.2±8.2 13.8±8.5 0.187 13.4±7.8 13.7±8.4 0.759
Data are expressed as No. of patients (%) or mean±SD. 
ABD = adjunct balloon dilation; IVUS = intravascular ultrasound; RVD = reference vessel diameter; SD = standard deviation; QCA = quantitative coronary 
angiographic.
DISCUSSION
Adjunct balloon dilation was not associated with MACE reduction at 1-year, even among 
patients requiring long EES implantation. However, significant interactions were observed 
among the subgroups for clinical presentation and vessel size. Adjunct balloon dilation after 
long EES implantation was more favored within the subset of patients with stable angina 
compared with those with acute coronary syndrome, and within the subset of lesions with 
small vessel compared with those with larger vessel.
Compared with angiography-guided EES implantation, IVUS-guided EES implantation 
resulted in a significantly lower rate of composite MACE at 1-year (5.8% vs. 2.9%, 
respectively; HR, 0.48; p=0.009) in the IVUS-XPL trial.9) This finding raised a question 
regarding the effectiveness of routine post-stent balloon dilation. However, it is unclear 
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Table 3. Clinical outcomes at 1-year post-procedure
Clinical outcomes
Total population Matched population
Patients, No (%)* HR (95% CI) p value Patients, No (%)
*
HR (95% CI) p value
ABD (+) ABD (−) ABD (+) ABD (−)
No. 1,061 611 - - 595 595 - -
MACE† 42 (4.1) 31 (5.1) 0.79 (0.50–1.26) 0.315 29 (4.9) 29 (4.9) 1.01 (0.60–1.69) 0.972
Cardiac death 4 (0.4) 5 (0.8) 0.47 (0.13–1.74) 0.246 3 (0.5) 4 (0.7) 0.76 (0.17–3.39) 0.718
Target lesion related MI 1 (0.1) 1 (0.2) 0.59 (0.04–9.36) 0.701 1 (0.2) 1 (0.2) 1.01 (0.06–16.16) 0.994
Ischemia-driven TLR 39 (3.8) 25 (3.9) 0.91 (0.55–1.50) 0.700 26 (4.4) 24 (4.0) 1.10 (0.63–1.91) 0.749
Definite or probable stent thrombosis 2 (0.2) 3 (0.5) 0.39 (0.07–2.31) 0.279 1 (0.2) 3 (0.5) 0.33 (0.04–3.21) 0.319
Acute 0 2 - - 0 2 - -
Sub-acute 1 0 - - 0 0 - -
Late 1 1 - - 1 1 - -
ABD = adjunct balloon dilation; CI = confidence interval; HR = hazard ratio; MACE = major adverse cardiac event; MI = myocardial infarction; TLR = target-lesion 
revascularization.
*Event rates are cumulative 1-year Kaplan-Meier event rates. HRs are derived from the Cox proportional hazard regression models, †MACE from cardiac death, 
target lesion-related myocardial infarction, or ischemia-driven TLR at 1-year.
No. at risk
Adjunct ballooning (+) 1,061 1,018 1,003 986 948 595 574 565 555 526
Adjunct ballooning (–) 611 593 583 570 535 595 578 569 556 523
Time (months)
Total populationA B
p=0.315
HR, 0.79 (95% CI, 0.50–1.26)
p=0.972
HR, 1.01 (95% CI, 0.60–1.69)
0 3 6 9 12
M
AC
E 
(%
)
6
4
2
Time (months)
Matched population
0 3 6 9 12
M
AC
E 
(%
)
6
4
2
Adjunct ballooning (+)
Adjunct ballooning (–)
Adjunct ballooning (+)
Adjunct ballooning (–)
Figure 1. Kaplan-Meier estimates of occurrence of MACEs for total population (A) and matched population (B). Cumulative incidence curves for MACEs of cardiac 
death, target lesion-related myocardial infarction, and TLR. 
CI = confidence interval; HR = hazard ratio; MACE = major adverse cardiac event; TLR = target-lesion revascularization.
whether routine post-stent balloon dilation would have achieved better clinical outcomes.15) 
Additionally, the clinical efficacy of this strategy has not been well evaluated in patients 
with second-generation DESs, although recent studies evaluated this strategy mostly 
among patients with bare-metal stents and first-generation DESs.7)8) Frobert et al.8) reported 
that post-stent balloon dilation was not associated with a significantly lower risk of stent 
thrombosis, but it was associated with a higher rate of restenosis in an analysis of 93,697 
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Adjunct ballon
dilation (+)
Adjunct ballon
dilation (–)
HR (95% CI) p forinteractionNo. of
events
No. of
patients
No. of
events
No. of
patients
All patients 29 595 29 595 1.01 (0.60–1.69)
Study 0.435
IVUS-XPL 23 508 23 460 0.91 (0.51–1.62)
RESET-long study 6 87 6 135 1.51 (0.49–4.69)
Age (years) 0.094
<65 18 306 11 293 1.59 (0.75–3.36)
≥65 11 289 18 302 0.64 (0.30–1.36)
Sex 0.300
Male 20 406 23 398 0.85 (0.47–1.56)
Female 9 189 6 197 1.61 (0.57–4.51)
Hypertension 0.655
Yes 16 380 17 369 0.91 (0.46–1.82)
No 13 215 12 226 1.16 (0.53–2.54)
DM 0.766
Yes 13 205 12 207 1.10 (0.50–2.41)
No 16 390 17 388 0.94 (0.48–1.86)
Clinical presentation 0.037
Stable angina 10 313 17 293 0.56 (0.25–1.22)
Acute coronary syndrome 19 282 12 302 1.72 (0.83–3.53)
Coronary arteries 0.050
LAD 10 363 17 358 0.58 (0.27–1.26)
LCX or RCA 19 232 12 237 1.68 (0.81–3.45)
Use of IVUS 0.511
Yes 5 272 6 242 0.75 (0.23–2.46)
No 24 323 23 353 1.16 (0.65–2.05)
RVD (mm) 0.027
<3.00 16 375 24 377 0.67 (0.36–1.26)
≥3.00 13 220 5 218 2.59 (0.92–7.27)
Lesion length (mm) 0.709
<40 21 473 19 459 1.08 (0.58–2.01)
≥40 8 122 10 136 0.86 (0.34–2.19)
Overlapping stent 0.382
Yes 8 173 12 197 0.73 (0.30–1.78)
No 21 422 17 398 1.19 (0.63–2.25)
Favors
adjunct ballooning
Favors
not adjunct ballooning
HR (95% CI)
1.00.50.1 2.0 5.0 10.0
Favors
adjunct ballooning
Favors
not adjunct ballooningHR
Figure 2. Subgroup analyses of the rates of MACEs at 1-year post-procedure. 
CI = confidence interval; DM = diabetes mellitus; HR = hazard ratio; IVUS = intravascular ultrasound; IVUS-XPL = Impact of intraVascular UltraSound guidance 
on outcomes of Xience Prime stents in Long lesions; LAD = left anterior descending; LCX = left circumflex; MACE = major adverse cardiac event; RCA = right 
coronary artery; RESET = REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation; RVD = 
reference vessel diameter.
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No. at risk
Adjunct ballooning (+) 313 303 299 297 286 282 271 266 258 240
Adjunct ballooning (–) 293 287 284 276 257 302 291 285 280 266
Time (months)
0 3 6 9 12
M
AC
E 
(%
)
6
4
2
Patients with stable angina
p=0.135
HR, 0.56 (95% CI, 0.25–1.22)
8
Time (months)
p for interaction=0.037
0 3 6 9 12
M
AC
E 
(%
)
6
4
2
p=0.139
HR, 1.72 (95% CI, 0.83–3.53)
Patients with acute coronary syndrome
8 Adjunct ballooning (+)
Adjunct ballooning (–)
Adjunct ballooning (+)
Adjunct ballooning (–)
A B
Figure 3. MACEs at 1-year post-procedure according to clinical presentation. Arrow indicates cardiac death and arrow head indicates myocardial infarction, and 
other events are TLR. 
CI = confidence interval; HR = hazard ratio; MACE = major adverse cardiac event; TLR = target-lesion revascularization.
No. at risk
Adjunct ballooning (+) 375 360 355 348 327 220 214 210 207 199
Adjunct ballooning (–) 377 367 362 351 320 218 211 207 205 203
Time (months)
0 3 6 9 12
M
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E 
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6
4
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RVD <3 mm
p=0.213
HR, 0.67 (95% CI, 0.36–1.26)
8
Time (months)
p for interaction=0.027
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Figure 4. MACEs at 1-year post-procedure according to vessel size. Arrow indicates cardiac death and arrow head indicates myocardial infarction, and other 
events are TLR. 
CI = confidence interval; HR = hazard ratio; MACE = major adverse cardiac event; RVD = reference vessel diameter; TLR = target-lesion revascularization.
stents (55,426 of bare-metal stents, 59%). Pasceri et al.7) compared clinical outcomes for 
DES-treated patients based on whether they received routine post-stent balloon dilatation 
(n=279) or selective post-stent balloon dilation after suboptimal results (n=262). The MACE 
incidence at 12 months was 19.5% in the selective post-stent balloon dilation group and 
12.5% in the routine post-stent balloon dilation group (p=0.040). This was mainly driven 
by lower TLR rates. However, in this study, first-generation DESs were used up to 55% of 
the time. There is no consistency in the practice of post-stent adjunct balloon dilation and 
the procedure varies according to the operators' discretion. Furthermore, adjunct balloon 
dilation was not routinely performed or discussed in prior studies on the use of DESs. From 
the Swedish coronary angiography and angioplasty registry, 63,740 of 93,697 stents (68%) 
were post-dilated following stent implantation.8) In the DEScover Registry involving 6,509 
patients treated with a first-generation DES in routine practice in the United States, post-
dilatation was performed for 46% of patients.16)
Our finding that post-stent adjunct balloon dilation was not associated with a reduction 
of MACEs at 1 year—even among patients with long lesions—could be attributed to the 
use of second-generation DESs in our trials, particularly EESs, which offer improved stent 
performance with different vascular healing and re-endothelialization properties.17)18) An optical 
coherence tomographic study reported that EES offered more favorable strut coverage than the 
first-generation sirolimus-eluting stent.18) A meta-analysis reported that the lowest rate of stent 
thrombosis was observed in the EES implantation among different types of DESs.19)
However, we also identified significant interactions in patients with stable angina (vs. acute 
coronary syndrome) and in patients with small vessel disease (vs. large vessel disease). 
Consistent with our findings, previous studies have shown that post-stent balloon dilation, 
was associated with an increased risk of death and myocardial infarction in patients with 
acute myocardial infarction but not in patients with stable angina.20) Patients presenting with 
acute coronary syndrome had plaques that were more unstable and had a higher volume of 
necrotic core according to virtual histology-IVUS compared with those presenting with stable 
angina.21) Post-intervention elevation of cardiac troponin levels was more frequently observed 
in lesions with a large necrotic core by ultrasound,22) and in lipid-rich lesions detected by 
near-infrared spectroscopy.23) Distal embolization due to aggressive mechanical expansion 
from post-stent balloon dilation may be a possible underlying mechanism.
Small vessels are still at high risk of restenosis even after receiving new-generation DESs.24)25) 
Post-procedural minimal lumen diameter by angiography is a major factor in restenosis 
after DES implantation.26)27) However, it is expected that the post-procedural minimal lumen 
diamater will be subsequently smaller in lesions of small vessels compared to those in large 
vessels. It is generally more difficult to obtain optimal acute angiographic results with a 
sufficient minimal lumen diameter. Additionally, the relatively acute gain in post-stent 
adjunct balloon dilation will be greater in lesions of small vessels compared to those of large 
vessels. Thus, routine post-stent adjunct balloon dilation may be more beneficial for lesions 
of small vessels treated with DES implantation than for lesions of large vessels. Furthermore, 
all patients enrolled in this study had diffuse long lesions. Diffuse long lesions, compared 
with focal lesions, have a higher probability of underlying plaques and heavy calcification. 
Besides the presence of heavy calcium and greater amounts of plaques, diffuse lesions have 
a greater chance of leading to small vessel diameter. This corresponds to the distal margin 
of long DES implantation and location in the middle or distal segment of major epicardial 
arteries, as well as requiring 2 more overlapping stents. Therefore, these subsets of small 
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vessels and long lesions with a high-risk of stent failure may require routine post-stent 
adjunct balloon dilation.
This study has several limitations. First, this study did not have a randomized comparison 
design. Second, our patient sample size and a 1-year clinical follow-up period may not be 
sufficient to assess clinical outcomes. Third, post-stent adjunct dilation performance after stent 
deployment was determined by corresponding physicians. However, all analyzed patients were 
drawn from 2 randomized trials, allowing us to minimize risk for any potential bias using an 
endpoint analysis with precisely defined criteria, using core laboratories, and blinding the event 
adjudication committee members to 1 another. Fourth, although we found some interaction in 
the subgroup analyses, our major findings need to be interpreted as negative results.
In conclusion, adjunct balloon dilation was not associated with MACE reduction at 1 year 
among patients requiring long coronary stent implantation. However, post-stent adjunct 
balloon dilation may be necessary for patients who present with stable angina or for lesions 
with small vessels requiring long EES implantation. Large randomized trials comparing the 
efficacy of routine post-stent adjunct balloon dilation are required.
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